The combination of good healthcare (95% of Colombian citizens have health insurance), an already strong clinical trial industry, stringent regulations issued in 2008 that requires sites to be certified by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) and a relatively quick and predictable approval process for launching a trial has made it a desirable clinical trial destination.
— Ronald Rosenberg, CenterWatch Weekly, April 6, 2015


Unparalleled benefits for your pharma, medtech or biotech startup.

  • Competitive costs: Savings of about 30% or more over trials costs in the US or Europe. Today's low Colombian peso exchange rate vs the US dollar makes the country even more cost-competitive. Read more
  • Fast and predictable national Ministry of Health regulatory pathway —about 30 days for medical devices and 90 days for pharma  after the local IRB approval. 
  • High enrollment rate: A 50-million population with universal health care coverage ensures a large patient pool of all ages.
  • Over 100 ICH/GCP-government-certified research sites with almost 30 years of experience and with the same quality and ethical standards that you would find in the U.S. and Europe. 
  • FDA acceptance of clinical data from Colombia (as long as it is gathered following ICH/GCP international guidelines). Read more
  • Fast product importation (free trade agreement with the U.S. and the E.U.).
  • Great geographical location: EST time zone, fast and direct airline connectivity from any major city.
  • Colombia has one of the four best health care systems in the world. Learn more.  
  • Colombia is a top destination for medical tourism. Learn more
  • Great healthcare infrastructure and business environment. Colombia has almost 50% of the best clinics and hospitals in Latin America. Learn more
  • Colombia is one of the top three countries in Latin America's on the World Bank's Ease of Doing Business annual report. Learn more
  • Highly motivated and experienced principal investigators —many of them are bilingual and trained in the US or Europe.
  • Generous government tax incentives: Life sciences startups that directly or indirectly create an entity in Colombia and invest in —or give donations to— R&D projects (e.g. clinical trials), can get a tax deduction of 175% of the amount invested and qualify for over $150 million available for grants in 2015. Read more
  • Colombia is a Latin-American leader in volume of clinical research and receives about 40 annual trials.
  • Learn more